The throughline of 2025 beauty and wellness dealmaking was discipline. The market produced fewer deals, but the ones that got done were increasingly strategic—built around capability acquisition, margin defense, and long-term category positioning rather than short-term growth optics. At the same time, persistent brand failures underscored a harsher truth: beauty may be resilient, but the ecosystem is no longer forgiving, and capital can’t be relied on to cover up fundamental flaws in a business model.
Heading into 2026, the winners will be the brands and investors who understand the new rules of value creation—where differentiation must be provable, distribution is harder-earned, and the convergence of beauty and wellness demands a fundamentally different underwriting lens.
1. Portfolio Optimization Will Create Both Orphans and Opportunities
Portfolio pruning will remain a primary driver of PE and strategic activity, with more groups actively divesting non-core assets—sometimes at distressed valuations, sometimes at surprisingly attractive ones. This dynamic will create fertile ground for new platform builders and opportunistic buyers, particularly as large strategics continue to simplify and refocus. Many of the brands that were once the darlings of the millennial growth cycle will become the orphans of 2026: decent businesses, but no longer aligned with the parent’s priorities or growth algorithm.
2. Fewer Deals, Higher Conviction—and Still Full Valuations
If 2025 proved anything, it’s that lower deal volume does not automatically translate to lower pricing. In 2026, the market will likely remain defined by fewer transactions but more intentional ones—where buyers are underwriting not just category growth but also durable differentiation, margin defense, and the ability to scale efficiently. Quality assets will still command premium valuations, while “good but not great” brands will find the market increasingly thin.
3. Capability Acquisitions Will Accelerate
Beauty has entered a new innovation cycle—one increasingly shaped by biotech, ingredient science, advanced manufacturing, and next-generation packaging. As a result, investors will continue shifting capital toward the infrastructure behind the brands: manufacturers, labs, ingredient suppliers, and enabling technologies that power speed-to-market and product differentiation. Expect supply-side M&A to re-accelerate, as strategics and PE firms look to “buy-size” capabilities that future-proof their portfolios and provide leverage across multiple brands and categories.
4. Cross-Border Capital Will Be A Deal Driver
International interest in U.S. beauty remains strong—particularly from Asian buyers—but many of these groups are disciplined and rarely overpay. That creates an opening for middle-of-the-road brands that may not attract a bidding war domestically but are attractive as strategic entry points. At the same time, capital flows will increasingly move in both directions: India became a major investment magnet in 2025, and the Middle East is emerging as a serious growth and innovation market. The value of the dollar will likely play into this trend - its decline in the early part of 2026 makes domestic deals slightly cheaper and international deals slightly more expensive - but this is prime arbitrage territory for global funds, platforms, and strategics.
5. The Market Will Split Between “Brand Winners” and “Execution Savants”
Capital will concentrate around two types of brands: those with exceptional lifestyle brand positioning and community-driven demand, and those with defensible moats—patents, proprietary technology, clinical proof, or unique IP. The other cohort attracting serious attention will be brands with execution advantages: vertical integration, owned distribution, superior margin structures, or operating leverage. The middle—the brands with great packaging, strong formulas, and strong growth but no defensible edge—will face the toughest funding and exit environment in years.
6. US Retail Will Continue to Pressure Brand Economics and Limit Luxury and Fragrance Deals
Retail has quietly become one of the biggest constraints on beauty growth and dealmaking. Consolidation has created an upper limit on shelf space at the exact moment the market has more brands than ever. With retailers holding exceptional leverage—and margin pressures rising—brands will face increasing demands around pricing, promotions, and trade spend. Luxury, in particular, has a structural bottleneck in the U.S.: there are still too few viable distribution homes for luxury fragrance and other high-end brands, limiting both category expansion and exit optionality - and therefore limiting deal activity.
7. Beauty + Wellness Convergence Will Force New Underwriting Models
The beauty-wellness convergence is no longer just a talking point at conferences—it’s an investment thesis that’s now being funded in earnest. Longevity, devices, nutrition, services, and biotechnology will pull more capital into adjacent categories, but these assets require different diligence frameworks. Investors will need to adapt underwriting to account for clinical validation, research timelines, regulatory risk, IP defensibility, and claims scrutiny—introducing a new risk/reward profile that traditional beauty dealmakers have not historically had to price in.
8. The “Almost Deals” of 2024 + 2025 Will Retreat—and the Exit Playbook Will Expand
Many of the most anticipated deals of 2024 and 2025 that never materialized will go quiet in 2026. Instead of pushing into a soft or uncertain market, many brands will spend the year retrenching—tightening operations, strengthening leadership, diversifying revenue streams, and building growth in new geographies, channels, and customer segments. For the largest brands, exit optionality may narrow further: by 2027, some will be too big for traditional strategic buyers, increasing pressure for alternative exits—secondary buyouts, minority recapitalizations, or even public-market pathways (though, historically, the public markets have been dangerous for most beauty companies).
